by nobilistx | Aug 27, 2019 | Uncategorized |
PORTLAND, Ore., August 27, 2019 – Nobilis Therapeutics announced today the issuance of the United States patent filed by the company in May of 2017. The patent number 10,376,539, titled “”AUGMENTATION OF ANTIINFLAMMATORY, IMMUNOMODULATORY, AND...
by nobilistx | Jul 17, 2019 | Uncategorized |
Nobilis Therapeutics is happy to announce that both of its submitted abstracts have been accepted to the Scientific Program at the 19th WPA World Congress of Psychiatry. The Congress is the official annual forum of the World Psychiatric Association that represents 140...
by nobilistx | Jan 10, 2019 | Uncategorized |
PORTLAND, Ore., January 10, 2019 (Newswire.com) – Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative Central Nervous System therapies based upon the use of noble gas mixtures, today announced that it has entered into a...
by nobilistx | Jan 6, 2019 | Uncategorized |
PRESS RELEASE JAN 7, 2019 01:00 PST PORTLAND, Ore., January 7, 2019 (PRNewswire.com) – Nobilis Therapeutics, a biopharmaceutical company focused on the advancement of innovative CNS therapies, today announced that it has filed an Investigational New...
by nobilistx | Jan 2, 2019 | Uncategorized |
Together with researchers from the Imperial College of London and the Third Medical Military University in China Nobilis Therapeutics has published the results of an in-vivo and in-vitro study of Argon use in diabetic wound model. The positive results of the study...
